Navigation Links
World-first high blood pressure treatment trialled in Melbourne
Date:4/3/2009

A world-first breakthrough to treat high blood pressure has been successfully trialled in Melbourne.

The clinical trial showed significant improvement in blood pressure of participants who were given a new catheter-based treatment where blood pressure lowering medication had failed.

Director of Monash University's Centre of Cardiovascular Research and Education in Therapeutics, Professor Henry Krum led the research collaboration between Monash, the Baker Heart and Diabetes Institute, and St Vincent's Hospital to develop the new surgical technique that disrupts nerves around the kidneys to dramatically reduce high blood pressure.

The technique could benefit those at high risk of heart attack or stroke from high blood pressure that resists conventional drug treatments.

Professor Krum presented these data in a late breaking clinical trial session at The American College of Cardiology's 58th Annual Scientific Session earlier this week and was lead author on a simultaneous publication in The Lancet.

The results are set to revolutionise high blood pressure treatment in patients around the world.

Professor Henry Krum said the treatment would benefit those five to twenty per cent of patients with high blood pressure who do not respond to medication.

"Patients who underwent the procedure had a significant reduction in their blood pressure levels and we were able therefore to reduce their risk of severe stroke or heart attack," Professor Krum said.

A total of 50 patients were recruited from Australia and overseas for the trial conducted by a team of researchers, which included Professor Henry Krum, from Monash University, Professor Markus Schlaich and Professor Murray Esler from Baker IDI and Professor Rob Whitbourn from St Vincent's Hospital, Melbourne.

Professor Krum said the trial results were the most significant in the treatment of high blood pressure since the introduction of the drugs that are in use today.

"We showed an excellent safety profile of this brief, catheter-based therapy. No long-term adverse events resulted from the procedure. Therapeutic renal denervation led to a large and persistant decrease in blood pressure, which was achieved in patients resistant to multiple existing hypertensive drug types. Moreover, reduction of blood pressure was evident as early as 1 month, was further reduced at 3 months, and persisted through subsequent assessments," Professor Krum said.

The procedure is carried out under local anaesthetic and uses radio energy frequency, delivered to the targeted nerve area via catheter. As a result the nerves are silenced in the renal artery, which supplies blood to the kidneys.

Researchers had long-believed that this region was a key regulator of blood pressure, but until these trial results the theory had not been successfully trialled.

"The catheter allowed us to target a very specific area to deliver the right amount of frequency to the nerves without damaging the surrounding areas," Professor Krum said.


'/>"/>

Contact: Samantha Blair
Samantha.blair@adm.monash.edu.au
61-399-034-841
Monash University
Source:Eurekalert

Related medicine news :

1. Breathing life into injured lungs: World-first technique will expand lung donor organ pool
2. Australian over-50s walk away memory problems in world-first trial
3. World-first discovery could help treat life-threatening tumors
4. Haemonetics Bolsters Blood Bank Information Management Portfolio With Acquisition of Altivation Software
5. Blood, Marrow Drive Offers Hope for Baseball Player, 15
6. Last step leading to blood cell formation elucidated
7. Blood protein may hold key to stopping tumor growth in cancer patients
8. Effort Could Lead to Blood Tests for Heart Problems
9. Blood test for brain injuries gains momentum
10. After heart attack, bone marrow stem cells increase blood flow within heart
11. Statin Might Help Fight Blood Clots in Veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Aerolib ... system for Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, ... education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning Management ...
(Date:1/19/2017)... ... ... cold weather here, many people will have to clear snow with snow blowers or shovels ... but they can be dangerous when used incorrectly. That’s why Amica Insurance is ... of snow blowers:, , When removing wet snow or debris from ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, ... were used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Marks E-QURE , s ... following similar agreements in Israel and Argentina ... 5 billion global market ... in medical devices for the treatment of advanced wound care, announced today it ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic ... clinical company developing therapeutics designed to preserve the ... patients, today confirmed plans to initiate a Phase ... modified-release reformulation of lovastatin lactone designed to reduce ... in the gut to treat the underlying ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology: